Author:
McKay R,Haider B,Duh M S,Valderrama A,Nakabayashi M,Fiorillo M,Ristovska L,Wen L,Kantoff P
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Urology,Oncology
Reference30 articles.
1. Herrera FG, Tawadros T, Berthold DR . Bone metastases in prostate cancer: pathophysiology, clinical complications, actual treatment, and future directions. In: Heymann D (ed). Bone Cancer: Primary Bone Cancers and Bone Metastases, 2nd edn. Elsevier Inc.: San Diego, CA; Elsevier/Academic Press: Waltham, MA, 2015.
2. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458–1468.
3. Fizazi K, Scher HI, Miller K, Basch E, Sternberg CN, Cella D et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol 2014; 15: 1147–1156.
4. Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012; 13: 1210–1217.
5. Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR et al. Metastatic prostate cancer and the bone: significance and therapeutic options. Eur Urol 2015; 68: 850–858.
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献